Latest news with #NaderKabbani
Yahoo
17-05-2025
- Business
- Yahoo
Hims & Hers Health (NYSE:HIMS) Sees 140% Stock Price Surge Over Past Month
Hims & Hers Health recently saw a significant stock price increase, jumping 140% over the past month. This rise coincided with key executive appointments, including Mo Elshenawy as Chief Technology Officer and Nader Kabbani as Chief Operations Officer, both bringing substantial experience to their roles. Additionally, a strong earnings report with Q1 sales nearly doubling year-over-year likely supported investor confidence. The new collaboration with Novo Nordisk to enhance obesity care aligns with their growth strategy. Even as the market climbed 5% recently, these internal developments may have amplified investor enthusiasm beyond broader market trends. Be aware that Hims & Hers Health is showing 2 warning signs in our investment analysis. Uncover 16 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent executive appointments at Hims & Hers Health coupled with the positive earnings report and innovative collaborations are shaping a promising narrative for potential growth. The increased focus on personalized telehealth offerings, aligning with these leadership changes, could drive revenue growth. The acquisition of facilities aimed at diversified treatment options suggests a proactive approach to enhancing healthcare services, potentially uplifting both revenue and earnings forecasts. Enhanced AI and technology investments further signal a push for improved diagnostic capabilities and increased market entrenchment. For context, Hims & Hers Health's total returns over the past three years display a very large increase of 1741.88%. This long-term performance outpaces broader market trends and underscores the company's growth trajectory. When comparing to performance metrics over the past year, Hims & Hers Health's returns surpassed the average return of the US Healthcare industry, indicating robust growth dynamics. While the current share price has seen an impressive climb of 140% recently, it is still trading at a discount of 17.6% relative to the analyst consensus price target of US$42.53. This suggests potential room for further price appreciation if the company's growth initiatives successfully translate into improved revenue, earnings, and market share. Ultimately, the ongoing developments create potential for Hims & Hers Health to continue its substantial trajectory, focusing on expanding its telehealth platform and maximizing market opportunities within a competitive landscape. According our valuation report, there's an indication that Hims & Hers Health's share price might be on the expensive side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:HIMS. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
13-05-2025
- Business
- Yahoo
Wall Street Punishes HIMS--Right After It Lands a Blockbuster Weight Loss Deal
Hims & Hers (NYSE:HIMS) just hit a major milestonepartnering with Novo Nordisk (NYSE:NVO) to offer branded Wegovy directly through its telehealth platform. It's a bold move that cements Hims' position in the exploding GLP-1 weight-loss space. Add to that a 38% year-over-year surge in subscribers to 2.37 million, and you'd expect the stock to fly. Instead, it fell in after-hours trading. Why? Because the company's second-quarter revenue guidance came in below Wall Street's expectations, and earnings per share missed. For now, the market is still demanding near-term execution over long-term ambition. Warning! GuruFocus has detected 1 Warning Sign with NVO. But dig deeper and a different story is unfolding. Over the past few years, Hims has quietly transformed its financial engine. The chart shows a clear and sustained upward trend in both operating and free cash flow, reversing prior losses and pointing to better financial discipline. While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of specialties, from sexual and mental health to dermatology and weight loss. The foundation is being laid, and the shift from growth-at-all-costs to sustainable growth is well underway. Now with former Amazon exec Nader Kabbani onboard as COOand a product roadmap expanding into menopause, low testosterone, sleep, diagnostics, and even longevityHims is positioning itself as the front-runner in personalized healthcare. CEO Andrew Dudum's long-term target? $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. That's a big betbut if execution keeps pace with vision, HIMS might just become one of the most transformative digital health platforms of the decade. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
07-05-2025
- Business
- San Francisco Chronicle
What's driving the roller coaster ride for San Francisco's Hims & Hers stock?
Shares of Hims & Hers have been on a wild ride recently. After a strong earnings report on Monday, the stock surged, only to sharply decline before rebounding again later on Tuesday morning. What's fueling the roller coaster ride? Several factors appear to be at play. Founded in 2017, Hims & Hers saw explosive growth during the COVID-19 pandemic by providing direct-to-consumer health care consultations and treatments for conditions like hair loss, erectile dysfunction and weight management. The company, which primarily targets millennials, went public in 2021. The company reported strong first-quarter earnings that exceeded analysts' expectations. Revenue surged more than 100% year-over-year to $586 million, driven by its expanding telehealth services in areas like hair loss, sexual health and mental well-being. Additionally, Hims & Hers posted a profit of 20 cents per share, surpassing the forecast of 12 cents. In another key development, Hims & Hers announced Nader Kabbani, a former Amazon executive, would take over as the company's new chief operating officer. Despite the positive results, the stock dipped in after-hours trading on Monday and only rebounded the following day. The reason? The company issued a cautious outlook for the second quarter, leading to concerns about its ability to maintain momentum. Hims & Hers expects second-quarter revenue to fall between $530 million and $550 million, below the $564 million that analysts anticipated. The tempered forecast has raised doubts about the company's future growth prospects. Along with its quarterly results, the San Francisco telehealth company has been making headlines for a variety of reasons. Andrew Dudum, the CEO and co-founder who grew up in San Francisco's West Portal, faced backlash for donating $1 million to Donald Trump's presidential inaugural committee earlier this year. The donation sparked criticism from deeply blue San Francisco, and it spilled over to Dudum's local business, George's Donuts & Merriment. The company also faced criticism over a Super Bowl ad for a compounded version of popular weight loss drugs Wegovy and Ozempic. Critics alleged the ad failed to adequetly disclose risks, side effects and safety information. Hims & Hers' ability to navigate these challenges will likely play a key role in determining its stock's performance in the coming months. 'We're starting 2025 with incredible momentum,' Dudum said in a statement Monday. 'We're building a platform that puts the individual at the center of every decision and others are taking notice. Over time, we expect wider collaboration across the industry, inclusive of pharmaceutical players, innovative leaders in diagnostic and preventative testing, and world class providers.'
Yahoo
06-05-2025
- Business
- Yahoo
Wall Street Punishes HIMS--Right After It Lands a Blockbuster Weight Loss Deal
Hims & Hers (NYSE:HIMS) just hit a major milestonepartnering with Novo Nordisk (NYSE:NVO) to offer branded Wegovy directly through its telehealth platform. It's a bold move that cements Hims' position in the exploding GLP-1 weight-loss space. Add to that a 38% year-over-year surge in subscribers to 2.37 million, and you'd expect the stock to fly. Instead, it fell in after-hours trading. Why? Because the company's second-quarter revenue guidance came in below Wall Street's expectations, and earnings per share missed. For now, the market is still demanding near-term execution over long-term ambition. But dig deeper and a different story is unfolding. Over the past few years, Hims has quietly transformed its financial engine. The chart shows a clear and sustained upward trend in both operating and free cash flow, reversing prior losses and pointing to better financial discipline. While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of specialties, from sexual and mental health to dermatology and weight loss. The foundation is being laid, and the shift from growth-at-all-costs to sustainable growth is well underway. Wall Street Punishes HIMS--Right After It Lands a Blockbuster Weight Loss Deal Now with former Amazon exec Nader Kabbani onboard as COOand a product roadmap expanding into menopause, low testosterone, sleep, diagnostics, and even longevityHims is positioning itself as the front-runner in personalized healthcare. CEO Andrew Dudum's long-term target? $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. That's a big betbut if execution keeps pace with vision, HIMS might just become one of the most transformative digital health platforms of the decade. This article first appeared on GuruFocus.
Yahoo
06-05-2025
- Business
- Yahoo
Hims & Hers Stock Jumps as Q1 Sales More Than Double
Cheng Xin / Getty Images Key Takeaways Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled. However, the health and wellness platform missed analysts' estimates for current-quarter sales on the impact of changes with its weight-loss treatments and sexual health specialty. Hims & Hers hired former Amazon executive Nader Kabbani to be COO. Hims & Hers Health (HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected results on soaring sales and subscribers. The company reported first-quarter earnings per share of $0.20, with revenue skyrocketing 111% year-over-year to $586.0 million. Both exceeded Visible Alpha estimates. Total subscribers grew 38% to 2.37 million, and monthly online revenue per average subscriber increased 53% to $84. Earlier, shares were trading lower when the company noted it expects current-quarter revenue to be in the range of $530.0 million to $550.0 million, while analysts were looking for $564.3 million, per Visible Alpha. The downbeat outlook came as Hims & Hers moves away from providing a version of the weight-loss drug in Novo Nordisk's (NVO) Wegovy and Ozempic and makes changes its plan for sexual health products. The company announced in February that it would stop offering a compounded treatment containing the obesity drug semaglutide after the first quarter following a Food and Drug Administration (FDA) decision that semaglutide was no longer in short supply. In addition, in a letter to shareholders, co-founder and CEO Andrew Dudum explained that the transition being made in the firm's Sexual Health specialty is designed "to align our investments toward long-term value creation, even if that results in temporary near-term headwinds for the business." The company separately said former Amazon executive Nader Kabbani would become Chief Operations Officer. Shares of Hims & Hers are up almost 90% this year. TradingView Read the original article on Investopedia
